Amgen Inc. stock falls 1.27% and underperforms rivals in mixed market session

9 articles · Updated · MarketWatch · Apr 27

Amgen shares closed at $340.18 on Monday, marking their second consecutive day of losses and finishing 13.06% below the 52-week high reached in March.
The stock's decline outpaced competitors Johnson & Johnson, Pfizer, and AbbVie, which also fell but to lesser extents during the session.
Trading volume for Amgen matched its 50-day average, while the broader market saw the S&P 500 edge higher and the Dow Jones slip slightly amid mixed trading.

Is Amgen's stock dip a buying opportunity before its new obesity drug launches?

Can Amgen's pipeline growth truly outpace the decline of its older blockbuster drugs?

How will Amgen's strategy combat Medicare price negotiations to protect future drug profits?

Why is Amgen's free cash flow projected to jump by an astounding 65% this year?

Will Amgen's monthly obesity drug successfully challenge the current market leaders?